Tisagenlecleucel is a CD19-directed autologous CAR-T therapy approved for relapsed/refractory (r/r) paediatric and young adult acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Here, CD19 is linked to acute lymphoblastic leukemia.